As you might know, Arcus Biosciences, Inc. (NYSE:RCUS) just kicked off its latest third-quarter results with some very strong numbers. Revenues of US$26m beat estimates by a substantial 28% margin. Unfortunately, Arcus Biosciences also reported a statutory loss of US$1.27 per share, which at least was smaller than the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there’s been a strong change in the company’s prospects, or if it’s business as usual. With this in mind, we’ve gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Taking into account the latest results, the eight analysts covering Arcus Biosciences provided…
